Author:
Boku N.,Ryu M.-H.,Kato K.,Chung H.C.,Minashi K.,Lee K.-W.,Cho H.,Kang W.K.,Komatsu Y.,Tsuda M.,Yamaguchi K.,Hara H.,Fumita S.,Azuma M.,Chen L.-T.,Kang Y.-K.
Funder
Ono Pharmaceutical Co., Ltd.
Reference34 articles.
1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0. IARC CancerBase No. 11. International Agency for Research on Cancer; http://globocan.iarc.fr (16 November 2018, date last accessed).
2. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology;Ajani;J Natl Compr Canc Netw,2016
3. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Smyth;Ann Oncol,2016
4. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer;Okines;Ann Oncol,2009
5. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer;Yamada;Ann Oncol,2015
Cited by
236 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献